User login

Colombia To Reduce Price Of Swiss Cancer Drug In Lieu Of Compulsory License

June 16, 2016 at 4:12 PM
The Colombian government Wednesday (June 15) moved to reduce the price of a Swiss-made cancer drug in a move that U.S. businesses claim runs afoul of the “spirit” of Colombia's trade commitments, but the government will not pursue a compulsory license for the drug, Colombian Health Minister Alejandro Gaviria said in a statement to Inside U.S. Trade. A Declaration of Public Interest issued Wednesday by Colombia's Ministry of Health intends to cut the price of the drug Glivec, produced...

Not a subscriber? You can request 30 days free access to exclusive, behind-the-scenes reporting on trade policy in the Biden era.